scholarly journals CMVpp65/gB Plasmid Vaccine ASP0113

2020 ◽  
Author(s):  
Keyword(s):  
Plasmid Vaccine

Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge

Vaccine ◽  
2003 ◽  
Vol 21 (11-12) ◽  
pp. 1099-1102 ◽  
Author(s):  
Laurent Fischer ◽  
Jean Philippe Tronel ◽  
Jules Minke ◽  
Simona Barzu ◽  
Philippe Baudu ◽  
...  
Keyword(s):  
Canine Distemper Virus ◽  
Canine Distemper ◽  
Virus Challenge ◽  
Plasmid Vaccine

scholarly journals Lack of Protection in Mice and Necrotizing Bronchointerstitial Pneumonia with Bronchiolitis in Guinea Pigs Immunized with Vaccines Directed against the hsp60 Molecule ofMycobacterium tuberculosis

2000 ◽  
Vol 68 (6) ◽  
pp. 3674-3679 ◽  
Author(s):  
Oliver C. Turner ◽  
Alan D. Roberts ◽  
Anthony A. Frank ◽  
Susan W. Phalen ◽  
David M. McMurray ◽  
...  
Keyword(s):  
Heat Shock ◽  
Guinea Pigs ◽  
Lung Damage ◽  
Dna Encoding ◽  
Protein Antigens ◽  
Plasmid Vaccine ◽  
Potential Vaccine ◽  
Guinea Pig Model ◽  
Shock Proteins ◽  
Severe Lung

ABSTRACT In this study, the hsp60 and hsp70 heat shock protein antigens ofMycobacterium tuberculosis were tested as potential vaccine candidates, using purified recombinant protein antigens or antigens encoded in the form of a DNA plasmid vaccine. Guinea pigs vaccinated with a mixture of the two proteins showed no evidence of resistance to low-dose aerosol challenge infection and quickly developed severe lung damage characterized by necrotizing bronchointerstitial pneumonia and bronchiolitis. As a result, we turned instead to a DNA vaccination approach using a plasmid encoding the hsp60 antigen of M. tuberculosis. Although immunogenic in mice, vaccination with plasmid DNA encoding hsp60 was not protective in that model or in the guinea pig model and again gave rise to similar severe lung damage. This study seriously questions the safety of vaccines against tuberculosis that target highly conserved heat shock proteins.

scholarly journals Localization within a Proline-Rich Antigen (Ag2/PRA) of Protective Antigenicity against Infection with Coccidioides immitis in Mice

2002 ◽  
Vol 70 (7) ◽  
pp. 3330-3335 ◽  
Author(s):  
Tao Peng ◽  
Lisa Shubitz ◽  
Julie Simons ◽  
Robert Perrill ◽  
Kris I. Orsborn ◽  
...  
Keyword(s):  
Humoral Response ◽  
Optimal Dose ◽  
Amino Acid Sequences ◽  
Full Length ◽  
Foreign Protein ◽  
Recombinant Vaccines ◽  
Coccidioides Immitis ◽  
Plasmid Vaccine ◽  
Multicomponent Vaccine ◽  
Total Immunoglobulin

ABSTRACT Subunits of a proline-rich coccidioidal antigen (Ag2/PRA) of Coccidioides immitis were analyzed by comparison as vaccines in mice. The optimal dose of plasmid vaccine encoding full-length Ag2/PRA was determined to be between 10 and 100 μg. Mice vaccinated with plasmids encoding amino acids (aa) 1 to 106 were as protective as full-length Ag2/PRA (aa 1 to 194). The subunit from aa 27 to 106 was significantly but less protective. Plasmids encoding aa 90 to 151 or aa 90 to 194 were not protective. Analogous results were obtained with recombinant vaccines of the same amino acid sequences. In addition, mixtures of aa 90 to 194 with either aa 1 to 106 or aa 27 to 106 did not enhance protection compared to the active single-recombinant subunits alone. Humoral response of total immunoglobulin G (IgG) and subclasses IgG1 and IgG2a were detectable in subunit vaccinations but at significantly (100-fold) lower concentrations than after vaccination with plasmids encoding full-length Ag2/PRA. Since virtually all protection by vaccination with full-length Ag2/PRA can be accounted for in the first half of the protein (aa 1 to 106), this subunit could make a multicomponent vaccine more feasible by reducing the quantity of protein per dose and the possibility of an untoward reactions to a foreign protein.

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques

Vaccine ◽  
2008 ◽  
Vol 26 (3) ◽  
pp. 440-448 ◽  
Author(s):  
Lauren A. Hirao ◽  
Ling Wu ◽  
Amir S. Khan ◽  
Abhishek Satishchandran ◽  
Ruxandra Draghia-Akli ◽  
...  
Keyword(s):  
Rhesus Macaques ◽  
Vaccine Delivery ◽  
Plasmid Vaccine ◽  
Subcutaneous Immunization

Determination of Tissue Distribution of an Intramuscular Plasmid Vaccine Using PCR and In Situ DNA Hybridization

1996 ◽  
Vol 7 (17) ◽  
pp. 2185-2194 ◽  
Author(s):  
R. A. Winegar ◽  
J. A. Monforte ◽  
K. D. Suing ◽  
K. G. O'loughlin ◽  
C. J. Rudd ◽  
...  
Keyword(s):  
Tissue Distribution ◽  
Dna Hybridization ◽  
Plasmid Vaccine

scholarly journals Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
Erin K. Quirk ◽  
Elizabeth L. Brown ◽  
Randi Y. Leavitt ◽  
Robin Mogg ◽  
Devan V. Mehrotra ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Events ◽  
Dna Vaccine ◽  
Low Grade ◽  
Clade B ◽  
Priming Phase ◽  
Plasmid Vaccine ◽  
Immunodeficiency Virus ◽  
Dna Plasmid ◽  
Phosphate Buffered Saline

Abstract The immunogenicity results from 3 phase I trials of the Merck DNA human immunodeficiency virus (HIV) vaccine have previously been reported. Because preventive DNA vaccine strategies continue to be leveraged for diverse infections, the safety and tolerability results from these studies can inform the field moving forward, particularly regarding adverse reactions and adjuvants. No serious vaccine-related adverse events were reported during the 3-dose priming phase. Pain at the injection site was more common with adjuvanted formulations than with the phosphate-buffered saline diluent alone. Febrile reactions were usually low grade. Although the AlPO4 or CRL1005 adjuvants used in these studies did not significantly enhance the immunogenicity of the DNA vaccine, adverse events were numerically more common with adjuvanted formulations than without adjuvants.

scholarly journals Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs

2005 ◽  
Vol 79 (1) ◽  
pp. 410-418 ◽  
Author(s):  
Yo Hoshino ◽  
Sarat K. Dalai ◽  
Kening Wang ◽  
Lesley Pesnicak ◽  
Tsz Y. Lau ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Guinea Pigs ◽  
Lipid A ◽  
Neutralizing Antibody ◽  
Wild Type Virus ◽  
Monophosphoryl Lipid A ◽  
Plasmid Vaccine ◽  
Simplex Virus ◽  
Herpes Simplex Virus 2

ABSTRACT Many candidate vaccines are effective in animal models of genital herpes simplex virus type 2 (HSV-2) infection. Among them, clinical trials showed moderate protection from genital disease with recombinant HSV-2 glycoprotein D (gD2) in alum-monophosphoryl lipid A adjuvant only in HSV women seronegative for both HSV-1 and HSV-2, encouraging development of additional vaccine options. Therefore, we undertook direct comparative studies of the prophylactic and therapeutic efficacies and immunogenicities of three different classes of candidate vaccines given in four regimens to two species of animals: recombinant gD2, a plasmid expressing gD2, and dl5-29, a replication-defective strain of HSV-2 with the essential genes UL5 and UL29 deleted. Both dl5-29 and gD2 were highly effective in attenuating acute and recurrent disease and reducing latent viral load, and both were superior to the plasmid vaccine alone or the plasmid vaccine followed by one dose of dl5-29. dl5-29 was also effective in treating established infections. Moreover, latent dl5-29 virus could not be detected by PCR in sacral ganglia from guinea pigs vaccinated intravaginally. Finally, dl5-29 was superior to gD2 in inducing higher neutralizing antibody titers and the more rapid accumulation of HSV-2-specific CD8+ T cells in trigeminal ganglia after challenge with wild-type virus. Given its efficacy, its defectiveness for latency, and its ability to induce rapid, virus-specific CD8+-T-cell responses, the dl5-29 vaccine may be a good candidate for early-phase human trials.

Sign in / Sign up

Export Citation Format

Share Document